The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

By N. Chalasani, Z. Younossi, J. Lavine, M. Charlton, K. Cusi, M. Rinella, S. Harrison, E. Brunt, A. Sanyal. Hepatology, 2018

6,253 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/fb6b3c68dd31d88a2c49a7d09388d956954046e0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. G. Targher
3. Christopher D. Byrne
4. Herbert Tilg
5. S. Friedman
6. Gerald I. Shulman
7. R. Loomba
8. E. Bugianesi

In Epidemiology

1. Z. Younossi
2. G. Targher
3. Christopher D. Byrne
4. Herbert Tilg
5. S. Friedman
6. Gerald I. Shulman
7. F. Tacke
8. R. Loomba

In Hepatology

1. S. Friedman
2. Z. Younossi
3. F. Tacke
4. Gerald I. Shulman
5. Christopher D. Byrne
6. G. Targher
7. R. Loomba
8. Herbert Tilg

Citations in the corpus

• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019, background): “(4) Over the next decade, it became increasingly clear that NAFLD is the hepatic manifestation of metabolic syndrome and is highly prevalent in obese and diabetic subjects.(5) Additionally, the increasing number of components of metabolic syndrome appear to increase the risk of progression to NASH.”
• Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. (2021, background): “Significant fibrosis was present in 11-18% of people at risk of alcohol-related liver disease [30].”
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020, neutral): “Musculoskeletal and connective-tissue disorders 0 1 (1) 3 (4) 1 (1)”
• Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, background): “[ 14] Although 95% of NAFLD patients have clinically overt metabolic abnormalities, about 5%, despite having hepatic steatosis, don’t have at least one cardio-metabolic risk (CMR).”
• NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, positive): “29 30 104 To date, there remains uncertainty about whether metformin reduces risk of major CVD events.”
• Mechanisms and disease consequences of nonalcoholic fatty liver disease (2021, background): “Affected people may have an echogenic liver on ultrasound or evidence of liver fat based on an imaging test that is noted incidentally or as part of a workup for right upper quadrant pain (Chalasani et al., 2018).”